Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections-Reference-Cited by-同舟云学术

Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections

Published:2017-03-03 Issue:4 Volume:14 Page:1095-1106
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Rolón Miriam¹,Serrano Dolores R.²³,Lalatsa Aikaterini⁴^ORCID,de Pablo Esther²,Torrado Juan Jose²³,Ballesteros Maria Paloma²³,Healy Anne Marie⁵,Vega Celeste¹,Coronel Cathia¹,Bolás-Fernández Francisco⁶,Dea-Ayuela Maria Auxiliadora⁷

Affiliation:

1. Centro para el Desarrollo de la Investigación Científica (CEDIC), Manduvirá 635 entre 15 de Agosto y O’Leary, 1255 Asunción, Paraguay

2. Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain

3. Instituto Universitario de Farmacia Industrial (IUFI), School of Pharmacy, University Complutense, Avenida Complutense, 28040 Madrid, Spain

4. School of Pharmacy and Biomedical Sciences, University of Portsmouth, St. Michael’s Building, White Swan Road, Portsmouth PO1 2DT, U.K.

5. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland

6. Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain

7. Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Edificio Seminario s/n, 46113 Moncada, Valencia, Spain

Funder

Ministerio de Asuntos Exteriores y de Cooperaci?n

Science Foundation Ireland

Ministerio de Educaci?n, Cultura y Deporte

Consejo Nacional de Ciencia y Tecnolog?a, Paraguay

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.6b01034

Reference43 articles.

1. WHO. Chagas disease (American trypanosomiasis). Available from:http://www.who.int/mediacentre/factsheets/fs340/en/. Accessed date: 17/02/2016. 2015.

2. In Vitro and in Vivo Antileishmanial and Trypanocidal Studies of New N-Benzene- and N-Naphthalenesulfonamide Derivatives

3. Chemotherapy of trypanosomiases and leishmaniasis

4. Effect of aggregation state on the toxicity of different amphotericin B preparations

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Promising Amphotericin B Derivative Induces Morphological Alterations, Mitochondrial Damage, and Oxidative Stress In Vitro and Prevents Mice from Death Produced by a Virulent Strain of Trypanosoma cruzi;Microorganisms;2024-05-24

2. From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease;International Journal of Molecular Sciences;2023-09-07

3. Continuous Manufacturing of Cocrystals Using 3D-Printed Microfluidic Chips Coupled with Spray Coating;Pharmaceuticals;2023-07-27

4. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers;International Journal of Pharmaceutics;2023-03

5. Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses;European Journal of Pharmaceutics and Biopharmaceutics;2023-02